Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Halozyme Therapeutics, Inc.

An update from Halozyme ( ($HALO) ) is now available. On September 22, 2026, Halozyme Therapeutics completed a $1.5 billion private offering of 1.5...

Halozyme Raises $1.5 Billion via Convertible Notes Offering

Halozyme ( ($HALO) ) has shared an update. On September 17, 2026, Halozyme Therapeutics, Inc. priced an upsized private offering of $1.3 billion in...

Halozyme Prices Upsized $1.3 Billion Convertible Notes Offering

There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on High Roller Technologies, Inc. (ROLR) and Halozyme (HALO) wi...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HALO	$113.90	-1.15%	1.96M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HALO	$113.90	-1.1%	1.96M
3
4
5
6

HALO

Get Halozyme Therapeutics, Inc. Data in Excel

Get Halozyme Therapeutics, Inc. Data in Excel